1. Home
  2. DUO vs ASBP Comparison

DUO vs ASBP Comparison

Compare DUO & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.08

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo Aspire Biopharma Holdings Inc.

ASBP

Aspire Biopharma Holdings Inc.

HOLD

Current Price

$0.88

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
ASBP
Founded
2011
2021
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.6M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
DUO
ASBP
Price
$1.08
$0.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
43.1K
167.8K
Earning Date
08-29-2025
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.05
52 Week High
$5.34
$2.45

Technical Indicators

Market Signals
Indicator
DUO
ASBP
Relative Strength Index (RSI) 43.82 39.61
Support Level $1.01 $0.12
Resistance Level $1.20 $0.88
Average True Range (ATR) 0.07 0.15
MACD 0.01 -0.06
Stochastic Oscillator 21.33 35.77

Price Performance

Historical Comparison
DUO
ASBP

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About ASBP Aspire Biopharma Holdings Inc.

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

Share on Social Networks: